ArticleAmerican journal of clinical dermatology2018
Comparison of Urticaria Activity Score Over 7 Days (UAS7) Values Obtained from Once-Daily and Twice-Daily Versions: Results from the ASSURE-CSU Study.
Article in American journal of clinical dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 74 citations in OpenAlex.
- Article
- Dermographometer assessment in children with urticaria.The World Allergy Organization journal · 2026Article
- Chronic urticaria and quality of life.Bioinformation · 2026Article
- Towards Personalised Therapy in Chronic Spontaneous Urticaria: Advancing From Endotype to Clinical Response.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Review
- Efficacy and safety of CT-P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16-week follow-up study.Clinical and translational allergy · 2025Article
- Can urticaria severity be used as a biomarker for transition from acute to chronic urticaria?Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Article
- Substantial psychosocial impairments in patients with chronic urticaria are associated with delayed referral to urticaria centers, non-academic treatments, and dietary changes.Allergologie select · 2025Article
- Jujube Oxymel for the Treatment of Chronic Spontaneous Urticaria: Efficacy and Safety.Advanced biomedical research · 2024Article
- Omalizumab in Chronic Spontaneous Urticaria: A Real-World Study on Effectiveness, Safety and Predictors of Treatment Outcome.Clinical, cosmetic and investigational dermatology · 2024Article
- Article
- Automatic Urticaria Activity Score: Deep Learning-Based Automatic Hive Counting for Urticaria Severity Assessment.JID innovations : skin science from molecules to population health · 2024Article
- Chronic Spontaneous Urticaria: How to Measure It and the Need to Define Treatment Success.Dermatology and therapy · 2023Review
- Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don't Know.American journal of clinical dermatology · 2023Review
- Association between serological indicators of past contacts with Herpesviridae and a slower resolution of chronic spontaneous urticaria in children.Croatian medical journal · 2023Observational
- Chronic Urticaria Treatment with Omalizumab-Verification of NLR, PLR, SIRI and SII as Biomarkers and Predictors of Treatment Efficacy.Journal of clinical medicine · 2023Article
- Efficacy of Different Dosing Regimens of IgE Targeted Biologic Omalizumab for Chronic Spontaneous Urticaria in Adult and Pediatric Populations: A Meta-Analysis.Healthcare (Basel, Switzerland) · 2022Article
- Rome IV Criteria-Defined Irritable Bowel Syndrome in Atopic Patients and the Effect of Anxiety and Depression: A Case-Control Study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Article
- Chronic spontaneous urticaria activity, impact and control as well as their changes are strongly linked, and these links are not affected by angioedema or comorbid inducible urticaria - Results from the validation of the Polish Urticaria Control Test.The World Allergy Organization journal · 2022Article
- A Comparative, Three-Arm, Randomized Clinical Trial to Evaluate the Effectiveness and Tolerability of Bilastine vs Fexofenadine vs Levocetirizine at the Standard Dose and Bilastine vs Fexofenadine at Higher Than the Standard Dose (Up-Dosing) vs Levocetirizine and Hydroxyzine (in Combination) in Patients with Chronic Spontaneous Urticaria.Clinical, cosmetic and investigational dermatology · 2022Article
- The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update.Handbook of experimental pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Urticaria Activity Score summed over 7 days (UAS7) assesses the itch severity and hive count in chronic spontaneous urticaria (CSU) using once- or twice-daily diary-based documentation.
objectiveThe aim of this study was to evaluate the comparability of twice-daily versus once-daily versions of the UAS and the resulting UAS7 values.
methodsData came from the ASSURE-CSU study. The twice-daily and once-daily UAS7 was calculated from morning and evening ratings, as well as from exact 24-h evening ratings of hive count and itch severity, respectively. Three UAS7 scores were computed: UAS7 twice daily (UAS7
resultsData from 614 patients were analyzed. All three versions of the UAS7 yielded very similar results, with a mean (standard deviation) UAS7
conclusionsThe once- and twice-daily UAS7 scores were highly consistent, supporting the use of either version when evaluating CSU activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.